Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the correct dose and safety of combining two new
cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or
refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet
been tested in combination for the treatment of lymphoma. The main goal of this study is to
determine the safety of the combination.